IPSEN (EPA:IPN) | WebDisclosure

Basculer en Français

8295	Companies
114810	Keywords
55260	Articles
62423	Press releases

Home
Companies
IPSEN

PRESS RELEASE

published on 10/23/2024 at 07:00, 29 days 2 hours ago

Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2024 et revoit à la hausse ses prévisions pour l'exercice en cours
BRIEF

published on 09/23/2024 at 11:01, 1 month 27 days ago

Parvus Asset Management crosses threshold in IPSEN SA

Euronext Paris Voting Rights Threshold Crossing Ipsen SA Parvus Asset Management
BRIEF

published on 09/23/2024 at 11:01, 1 month 27 days ago

Franchissement de seuil par Parvus Asset Management dans IPSEN SA

Euronext Paris Droits De Vote Franchissement De Seuil Ipsen SA Parvus Asset Management
PRESS RELEASE

published on 09/23/2024 at 10:56, 1 month 27 days ago

Franchissement de seuil
Déclaration de franchissement de seuil par Parvus Asset Management Europe Limited pour le compte de clients et fonds détenant 7,80% du capital d'IPSEN SA

Droits De Vote Franchissement De Seuil Ipsen SA Parvus Asset Management Cession Actions
BRIEF

published on 09/16/2024 at 14:50, 2 months 4 days ago

Promising results for Cabometyx in advanced neuroendocrine tumors

Phase III Ipsen Neuroendocrine Tumors ESMO 2024 Cabometyx
BRIEF

published on 09/16/2024 at 14:50, 2 months 4 days ago

Des résultats prometteurs pour Cabometyx dans les tumeurs neuroendocrines avancées

Phase III Ipsen Tumeurs Neuroendocrines ESMO 2024 Cabometyx
PRESS RELEASE

published on 09/16/2024 at 14:45, 2 months 4 days ago

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
Final results from CABINET Phase III trial show significant reduction in disease progression or death risk with Cabometyx in advanced neuroendocrine tumors. Data presented at ESMO 2024 and NEJM

Phase III Trial Neuroendocrine Tumors ESMO 2024 Cabometyx Disease Progression
PRESS RELEASE

published on 09/16/2024 at 14:45, 2 months 4 days ago

Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées
Les résultats finaux de l’essai de Phase III CABINET confirment l’efficacité de Cabometyx dans les tumeurs neuroendocrines avancées. Ipsen publie les données au congrès ESMO 2024

Essai Clinique Ipsen Tumeurs Neuroendocrines ESMO 2024 Cabometyx
BRIEF

published on 09/15/2024 at 14:50, 2 months 5 days ago

New analysis of the CONTACT-02 trial by Ipsen

Clinical Trial Ipsen Prostate Cancer CONTACT-02 Cabometyx
BRIEF

published on 09/15/2024 at 14:50, 2 months 5 days ago

Nouvelle analyse de l'essai CONTACT-02 par Ipsen

Essai Clinique Ipsen Cancer De La Prostate CONTACT-02 Cabometyx

Accesswire

Published on 11/21/2024 at 09:00, 59 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 24 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 34 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 59 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 59 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:41, 18 minutes ago

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 09:01, 58 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 59 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 59 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 44 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 1 minute ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours 1 minute ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 3 hours 1 minute ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 52 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 39 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE